Liquid biopsy is routinely used to detect epidermal growth factor receptor mutations in advanced or metastatic lung cancer, due to some limitations of tissue genotyping, especially at relapse. However, the existence of a non-marginal proportion of oncogene-addicted lung cancers that can benefit from target therapy is rapidly expanding clinical relevance of plasma genotyping. Apart from static assessment of mutations in circulating free DNA, the fact that liquid biopsy is minimally invasive and can be repeated several times makes it a suitable assay for the dynamic monitoring of cancer response to treatment. It is likely that quantitative mutation assessment by liquid biopsy will be increasingly included in the design of innovative clinical trials for patient stratification purposes.

中文翻译：

---

非小细胞肺癌患者中液体活检的使用不断发展。

由于组织基因分型的某些限制，特别是在复发时，液体活检通常用于检测晚期或转移性肺癌中的表皮生长因子受体突变。然而，可以从靶标治疗中受益的非边缘比例致癌基因肺癌的存在正在迅速扩大血浆基因分型的临床相关性。除了静态评估循环游离DNA中的突变外，液体活检具有微创性并且可以重复多次，这一事实使其成为动态监测癌症对治疗反应的合适方法。通过液体活检进行定量突变评估可能会越来越多地包括在出于患者分层目的的创新性临床试验设计中。